229 related articles for article (PubMed ID: 26900152)
21. Structures of Mycobacterium tuberculosis FadD10 protein reveal a new type of adenylate-forming enzyme.
Liu Z; Ioerger TR; Wang F; Sacchettini JC
J Biol Chem; 2013 Jun; 288(25):18473-83. PubMed ID: 23625916
[TBL] [Abstract][Full Text] [Related]
22. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria.
Alahari A; Trivelli X; Guérardel Y; Dover LG; Besra GS; Sacchettini JC; Reynolds RC; Coxon GD; Kremer L
PLoS One; 2007 Dec; 2(12):e1343. PubMed ID: 18094751
[TBL] [Abstract][Full Text] [Related]
23. Structure-based inhibitor design of AccD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis.
Lin TW; Melgar MM; Kurth D; Swamidass SJ; Purdon J; Tseng T; Gago G; Baldi P; Gramajo H; Tsai SC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3072-7. PubMed ID: 16492739
[TBL] [Abstract][Full Text] [Related]
24. Mycolyltransferase from
Goins CM; Dajnowicz S; Smith MD; Parks JM; Ronning DR
J Biol Chem; 2018 Mar; 293(10):3651-3662. PubMed ID: 29352107
[No Abstract] [Full Text] [Related]
25. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
26. Active site conformational changes upon reaction intermediate biotinyl-5'-AMP binding in biotin protein ligase from Mycobacterium tuberculosis.
Ma Q; Akhter Y; Wilmanns M; Ehebauer MT
Protein Sci; 2014 Jul; 23(7):932-9. PubMed ID: 24723382
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.
Mdluli K; Slayden RA; Zhu Y; Ramaswamy S; Pan X; Mead D; Crane DD; Musser JM; Barry CE
Science; 1998 Jun; 280(5369):1607-10. PubMed ID: 9616124
[TBL] [Abstract][Full Text] [Related]
28. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
[TBL] [Abstract][Full Text] [Related]
29. A piperidinol-containing molecule is active against
Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
[No Abstract] [Full Text] [Related]
30. Multi-omics Investigation into the Mechanism of Action of an Anti-tubercular Fatty Acid Analogue.
Sakallioglu IT; Maroli AS; De Lima Leite A; Marshall DD; Evans BW; Zinniel DK; Dussault PH; Barletta RG; Powers R
J Am Chem Soc; 2022 Nov; 144(46):21157-21173. PubMed ID: 36367461
[TBL] [Abstract][Full Text] [Related]
31. Crystallization and preliminary X-ray crystallographic studies of the N-terminal domain of FadD28, a fatty-acyl AMP ligase from Mycobacterium tuberculosis.
Goyal A; Yousuf M; Rajakumara E; Arora P; Gokhale RS; Sankaranarayanan R
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Apr; 62(Pt 4):350-2. PubMed ID: 16582482
[TBL] [Abstract][Full Text] [Related]
32. Development of small-molecule inhibitors of fatty acyl-AMP and fatty acyl-CoA ligases in Mycobacterium tuberculosis.
Baran M; Grimes KD; Sibbald PA; Fu P; Boshoff HIM; Wilson DJ; Aldrich CC
Eur J Med Chem; 2020 Sep; 201():112408. PubMed ID: 32574901
[TBL] [Abstract][Full Text] [Related]
33. Further insight into S-adenosylmethionine-dependent methyltransferases: structural characterization of Hma, an enzyme essential for the biosynthesis of oxygenated mycolic acids in Mycobacterium tuberculosis.
Boissier F; Bardou F; Guillet V; Uttenweiler-Joseph S; Daffé M; Quémard A; Mourey L
J Biol Chem; 2006 Feb; 281(7):4434-45. PubMed ID: 16356931
[TBL] [Abstract][Full Text] [Related]
34. Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.
Luckner SR; Machutta CA; Tonge PJ; Kisker C
Structure; 2009 Jul; 17(7):1004-13. PubMed ID: 19604480
[TBL] [Abstract][Full Text] [Related]
35. Molecular basis of the functional divergence of fatty acyl-AMP ligase biosynthetic enzymes of Mycobacterium tuberculosis.
Goyal A; Verma P; Anandhakrishnan M; Gokhale RS; Sankaranarayanan R
J Mol Biol; 2012 Feb; 416(2):221-38. PubMed ID: 22206988
[TBL] [Abstract][Full Text] [Related]
36. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
[TBL] [Abstract][Full Text] [Related]
37. Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.
Reingewertz TH; Meyer T; McIntosh F; Sullivan J; Meir M; Chang YF; Behr MA; Barkan D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767723
[TBL] [Abstract][Full Text] [Related]
38. Crystal structures of FadD32 and pks13-ACP domain from Corynebacterium diphtheriae.
Chen R; Yuan J; Shi X; Tang W; Liu X
Biochem Biophys Res Commun; 2022 Jan; 590():152-157. PubMed ID: 34974304
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
He X; Alian A; Ortiz de Montellano PR
Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
[TBL] [Abstract][Full Text] [Related]
40. Structure-function analysis of the acyl carrier protein synthase (AcpS) from Mycobacterium tuberculosis.
Dym O; Albeck S; Peleg Y; Schwarz A; Shakked Z; Burstein Y; Zimhony O
J Mol Biol; 2009 Nov; 393(4):937-50. PubMed ID: 19733180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
